The Grifols Bioscience division is dedicated to hemotherapy, or the treatment of medical conditions using blood or blood components. Grifols’ hemotherapy products are made from human plasma, the liquid portion of human blood that contains essential proteins required for normal physical and neurologic function.
Grifols extracts the proteins from human plasma and uses them to produce therapeutic medicines for the treatment of rare, chronic and life-threatening conditions.
Their therapies treat a variety of medical conditions, including coagulation disorders, immune deficiencies, pulmonary disorders, liver cirrhosis, shock and trauma, and exposure to infections & diseases such as rabies, hepatitis and tetanus.
The Bioscience division oversees all activities related to our hemotherapy products, including plasma collection and manufacturing; plasma testing and analysis; research & development; manufacturing; marketing and worldwide distribution.
Grifols Bioscience is recognized by healthcare professionals and patients around the world for the quality, efficacy and safety of its plasma therapies; products which improve the health and well-being of millions of patients.
Please contact us if you would like further information on the Grifols product range.
Additional product details can also be found on www.grifols.com